We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Feb 2023 - 09 Feb 2023

Multi-Cancer Detection Blood Test to Enable Early Diagnosis and Treatment

By LabMedica International staff writers
Posted on 04 Jan 2023
Print article
Image: The OverC MCDBT has been granted Breakthrough Device Designation by the US FDA (Photo courtesy of Burning Rock)
Image: The OverC MCDBT has been granted Breakthrough Device Designation by the US FDA (Photo courtesy of Burning Rock)

The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to a Multi-Cancer Detection Blood Test (MCDBT) that is intended for early detection of multiple cancer types (esophageal, liver, lung, ovarian, and pancreatic cancers) in adults of either sex, aged 50-75 years old, at average risk for cancer.

In May 2022, Burning Rock Biotech Limited (Shanghai, China) had received CE mark for its OverC MCDBT manufactured in both its US and China facilities. Now, the FDA Breakthrough Device Designation granted for OverC MCDBT will pave the way for a clearer registration path through confirmative performance validation and utility establishment. Burning Rock’s OverC MCDBT demonstrated 69.1% sensitivity and 98.9% specificity in the case-control study, THUNDER, and will be further validated in prospective interventional studies among asymptomatic population. Test results of "Detected" with the top one or two predicted tissues of origin of cancer-associated signals may indicate the presence of cancer and should be followed up by diagnostic tests suggested by qualified healthcare professionals in accordance with professional guidelines. Test results of "Undetected" do not rule out the presence of cancer, and individuals should continue with guideline-recommended standard of care screening tests.

Compared with conventional cancer screening methods, liquid biopsy has the potential to increase detection efficiency and enable early diagnosis and treatment, thus improving patients' survival and quality of life while reducing social burden of the disease. Burning Rock had begun the development of multi-cancer early detection technology based on DNA methylation in 2016, and the technology and validation data have been presented at ASCO, ESMO and other medical conferences, as well as journals such as Nature Biomedical Engineering, demonstrating high specificity, sensitivity, and accuracy in predicting the tissue of origin.

“We are very excited that our cfDNA methylation multi-cancer early detection technology has received FDA Breakthrough Device Designation. For cancer, early diagnosis and treatment are the key to the long-term survival of patients. Liquid biopsy-based early detection technology will be an important supplement to the current cancer screening methods, especially for ovarian cancer, pancreatic cancer and other cancers that have no effective screening methods up to now,” said Mr. Yusheng Han, founder and CEO of Burning Rock. “Burning Rock has also launched two prospectively collected case-control studies, PREDICT and PRESCIENT, with more than 10,000 subjects to be enrolled, to continue developing OverC MCDBT to cover more cancer types. With our promising clinical research data, we believe that over time our collective effort is going to make significant impact towards the improvement of cancer patients' lifespan and quality of life.”

Related Links:
Burning Rock Biotech Limited 

New
Platinum Supplier
Laboratory Quality Control
Acusera
New
Human IgE Immunochromatography Test
ImmuneCheck IgE
New
Clinical Centrifuge
BenchMate C6V
New
Auto Mass Spectrometry Microbial Identification System
Microbe LW MS-5000

Print article
MEDLAB - INFORMA

Channels

Immunology

view channel
Image: Scientists have won USD 9.5 million to study emerging pathogens (Photo courtesy of Pexels)

Study of Emerging Pathogens to Better Understand Influenza-Antibody Interactions Could Improve Diagnostics

Outbreaks of Avian influenza have occurred around the world for over a century. The highly pathogenic H5N1 virus which was first identified in 1996 can lead to severe disease and has a high fatality rate... Read more

Microbiology

view channel
Image: Medical illustration of Carbapenem-resistant Enterobacteriacea (Photo courtesy of CDC, Stephanie Rossow)

Breakthrough Test Enables Targeted Antibiotic Therapy for Various Enterobacter Species

Bacteria of the Enterobacter genus are considered to be the most dangerous bacteria linked to hospital infections across the world. Some of their representatives demonstrate high resistance to commonly-used... Read more

Technology

view channel
Image: Flexible copper sensor made cheaply from ordinary materials (Photo courtesy of University of São Paulo)

Low-Cost Portable Sensor Detects Heavy Metals in Sweat

Heavy metals like lead and cadmium can be found in batteries, cosmetics, food and many other things that have become a part of daily life. However, they become toxic if they accumulate in the human body... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.